January 16, 2020
Bigfoot Biomedical, a diabetes startup looking to automate insulin delivery via a connected insulin pen, has kicked off its Series C round with an initial tranche of $45 million. The raise is headed once again by Abbott, with prior backers Quadrant Capital Advisors, Senvest Capital, Janus Henderson and Cormorant Asset Management pitching in once again.
Alongside the news of its raise, Bigfoot...
October 14, 2019
This morning med tech giant Abbott announced a new deal with chronic care management company Omada Health that will integrate Abbott’s FreeStyle Libre continuous glucose monitor (CGM) with Omada's health coaching platform.
Going forward, eligible users with Type 2 diabetes will have the option to integrate data from their FreeStyle Libre, including glucose reading, trends and patterns, with...
September 19, 2019
Sanofi has been active in the digital space this week inking two big deals: one with tech company Abbott and the other with digital platform Happify.
The first partnership with Abbott will combine the medtech company’s FreeStyle Libre, a continuous glucose monitoring system, and the pharma giant’s insulin dosing information to create smart pens and insulin titration apps.
Sanofi is currently...
July 17, 2019
Following a major sales bump in the second quarter of 2019, Abbott Laboratories is planning to significantly ramp up manufacturing for its FreeStyle Libre continuous glucose monitoring system, the company shared during an investor’s call this morning.
Specifically, the company highlighted a 72.9% increase in organic sales growth during the three-month period, reaching a worldwide total sales...
February 20, 2019
Novo Nordisk’s connected insulin pens will integrate with the Abbott Freestyle Libre system, allowing Freestyle Libre users to see data about their insulin alongside their glucose readings, the companies announced this morning.
"Lack of reliable information is a cause of huge frustration for many people with diabetes and their doctors," Anders Dyhr Toft, CVP of commercial innovation at Novo...
December 26, 2018
The pharma industry has become increasingly interested in the digital health space over the last few years, but this quarter numerous projects that have been in the works for years have finally came to fruition. For instance, Pear's reSET, the first digital therapeutic cleared by the FDA, was recently launched to commercial markets.
But that wasn’t the only advance in the space as pharma...
November 1, 2018
Just a short while after securing a CE Mark for its second generation device, Abbott has been granted FDA clearance for FreeStyle LibreLink, a companion mobile app for its 10 to 14-day CGM.
The launch adds a long-awaited feature for US users that’s been available for some time in Europe: users will be able to scan their sensors with an app on their smartphone — and see their latest reading —...
October 1, 2018
Abbott has received CE Mark clearance for the second generation of its Freestyle Libre device, which will allow the company to make the device available to users in Europe. It will be rolled out gradually in Europe starting in the next few weeks, and it will be offered as the same price as the first generation device.
Freestyle Libre 1, which has been available in Europe since 2014, is a fully...
September 5, 2018
Correction: A previous version of this article failed to specify that the deal concerns Freestyle Libre Pro, rather than the consumer version, Freestyle Libre.
Livongo Health, the digital chronic disease management company founded by former Allscripts CEO Glen Tullman, announced today that it will be the first United States enterprise diabetes management company to bring Abbott’s Freestyle Libre...